Stada 
Welcome,         Profile    Billing    Logout  
 17 Products   41 Diseases  17 Products   28 Trials   1191 News 
49 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tarpeyo (budesonide) / Calliditas, Stada
NefXtend, NCT06712407: Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

Recruiting
4
60
US
TARPEYO®, delayed-release budesonide capsules
Calliditas Therapeutics AB, Worldwide Clinical Trials
IgA Nephropathy
05/26
11/27
BAIN, NCT07030894: Nefecon and Ambrisentan in IgA Nephropathy

Not yet recruiting
4
129
NA
"Nefecon®","Ambrisentan"
The First Hospital of Jilin University
IgA Nephropathy, Chronic Kidney Disease, Proteinuria
12/26
12/26
Nefigard, NCT03643965 / 2017-004902-16: Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

Completed
3
365
Europe, Canada, US, RoW
Nefecon, Budesonide modified released capsule, Placebo oral capsule, Placebo
Calliditas Therapeutics AB
Primary IgA Nephropathy
07/23
07/23
Nefigard-OLE, NCT04541043 / 2020-003308-14: Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301

Completed
3
119
Europe, Canada, US, RoW
Nefecon 16mg daily
Calliditas Therapeutics AB
Primary IgA Nephropathy
02/24
02/24
NCT05534919: Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301

Completed
3
21
RoW
Nefecon
Everest Medicines (Singapore) Pte. Ltd.
Primary Immunoglobulin a Nephropathy (IgAN)
07/24
07/24
NCT06922305: Relative Bioavailability Study of HR19042 in Healthy Subjects

Completed
1
18
RoW
HR19042 Capsule, Tarpeyo®, Budenofalk®
Jiangsu HengRui Medicine Co., Ltd.
Primary IgA Nephropathy; Autoimmune Hepatitis
01/24
01/24
NCT06589752: Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN

Completed
N/A
200
RoW
TARPEYO 4 MG Delayed Release Oral Capsule, RAS inhibitor
Ruijin Hospital
Primary IgA Nephropathy
09/24
09/24
Apokyn (apomorphine bolus injection) / Stada, Supernus Pharma, Aguettant
2010-019198-14: Icke-motoriska och hälsoekonomiska effekter av intermittent subkutan apomorfinbehandling vid Parkinsons sjukdom

Ongoing
4
30
Europe
Apo-GO Pen, Apo-GO Pen, Apo-GO Pen
Karolinska Universitetssjukhuset Huddinge
Parkinsons sjukdom
 
 
APOMORPHEE, NCT02940912: Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease

Completed
4
45
Europe
Apomorphine, Apokinon, Placebo, Physiologic Serum
Clinique Beau Soleil
Parkinson Disease
01/21
04/21
2010-018650-12: Evaluation du système noradrénergique dans l’altération de la perception douloureuse chez le patient Parkinsonien

Ongoing
3
36
Europe
duloxetine, apomorphine, levodopa, dompéridone, CYMBALTA, APOKINON, MODOPAR, MOTILIUM, CYMBALTA, APOKINON, MODOPAR, MOTILIUM
CHU de Toulouse
maladie de Parkinson
 
 
2016-002454-20: Apomorphine Pump in Early Stage of Parkinson’s Disease Pompe à apomorphine au stade précoce de la maladie de Parkinson

Ongoing
3
192
Europe
APOKINON, Solution for infusion, APOKINON
CHU de Rennes, CHU de Rennes
Parkinson’s disease Maladie de Parkinson, Parkinson’s disease Maladie de Parkinson, Diseases [C] - Nervous System Diseases [C10]
 
 
EARLY-PUMP, NCT02864004: Apomorphine Pump in Early Stage of Parkinson's Disease

Active, not recruiting
3
134
Europe
Apomorphine, Apokinon, Best Medical Treatment
Rennes University Hospital
Parkinson's Disease
12/23
01/25
2004-001929-20: EL TEST DE APOMORFINA COMO MARCADOR BIOLÓGICO DE LAS RECAÍDAS EN PACIENTES DEPENDIENTES DE SUSTANCIAS PSICOTROPAS

Ongoing
2
180
Europe
Ialoprida, APO-go PEN 10 mg/ml solución inyectable, 123I-IBZM, APO-go PEN 10 mg/ml solución inyectable, 123I-IBZM
Servicio de Psiquiatría. Hospital Universitari Vall d’Hebron
Dependencia de alcoholDependencia de cocaínaDependencia de heroína
 
 
APPROVE, NCT06954428: Clinical Trial of Intranasal Delivery of NT-301

Not yet recruiting
1
48
RoW
NT-301 1 mg, NT-301 2 mg, Movapo pen, Placebo 1 mg, Placebo 2 mg, Placebo 3 mg, NT-301 3 mg, NT-301 4 mg, BA NT-301 Nasal spray, Placebo 4 mg
Nano PharmaSolutions Australia
Tolerability of NT-301 Nasal Spray, Pharmacokinetics of NT-301 Nasal Spray, Safety of NT-301 Nasal Spray, Performance of NT-301 Nasal Spray Device
10/25
10/25
Retacrit (epoetin alfa-epbx) / Stada, Norbitec, Pfizer
NCI-2009-01173, NCT00843882: Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Active, not recruiting
3
247
US
Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Epoetin Alfa, EPO, Epoetin alfa-epbx, Epogen, Eprex, Procrit, Retacrit, Laboratory Biomarker Analysis, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid
National Cancer Institute (NCI)
Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome
07/19
10/25
Alymsys (bevacizumab-maly) / Amneal, Pharmaceutical Libbs, Insud Pharma, Nichi-Iko, Stada
NCT04408989: A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and US Licensed-Avastin®.

Completed
1
114
RoW
MB02-SP, MB02-SP (Bevacizumab Biosimilar), MB02-DM, MB02-DM (Bevacizumab Biosimilar), US licenced Avastin®, Bevacizumab (US sourced)
mAbxience Research S.L.
Healthy Volunteers
08/21
09/21
NCT06313268: Safety of Effivia®, a Bevacizumab Biosimilar

Completed
N/A
83
RoW
Bevacizumab Biosimilar MB02, Effivia®
Laboratorios Liomont, Servicios Especializados en Ensayos Clínicos, S.C.
Metastatic Colorectal Cancer, Metastatic Cervical Cancer, Non Squamous Non Small Cell Lung Cancer
04/24
09/24
APO-go (apomorphine continuous subcutaneous infusion) / Stada, Kyowa Kirin, Endo, Supernus Pharma
INFUS-ON, NCT02339064: Infusion of Apomorphine: Long-term Safety Study

Active, not recruiting
3
99
US
apomorphine infusion
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Idiopathic Parkinson's Disease
12/18
12/25
APODoC, NCT05213169: Apomorphine in Severe Brain-injured Patients

Recruiting
2/3
48
Europe
Apomorphine Hydrochloride 5mg/ml, Sodium chloride 9mg/ml
University of Liege, Centre Hospitalier Neurologique William Lennox (Belgium), Hôpital Valdor - ISoSL (Belgium), VITHAS hospitales (Spain)
Disorder of Consciousness
12/26
12/26
2018-003144-23: Treating severe brain-injured patients with apomorphine Traitement des patients cérébro-lésés avec l'apomorphine

Not yet recruiting
2
54
Europe
Solution for infusion in pre-filled syringe, APO-go® PFS 5 mg/ml Solution for Infusion in Pre-filled Syringe
University of Liège, NeuroHealing Pharmaceuticals Inc., Britannia Pharmaceuticals Limited
Disorders of consciousness Troubles de l'état de conscience, Disorders of consciousness Troubles de la conscience, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT03623828: Treating Severe Brain-injured Patients With Apomorphine

Active, not recruiting
2
8
Europe
Apomorphine Hydrochloride 50Mg/10mL Prefilled Syringe, APO-go PFS 5mg/ml
University of Liege, Université Catholique de Louvain
Disorder of Consciousness
04/21
11/22
2019-003315-60: A study investigating the effect and safety of a new potential drug for Parkinson's disease patients.

Ongoing
1/2
46
Europe
APO-go®, APORON, Solution for injection/infusion, Suspension and solution for spray, Apo-go
Criceto IKM B.V., Criceto
Parkinson's Disease, Parkinson, Diseases [C] - Nervous System Diseases [C10]
 
 
AUTAP, NCT05405998: Development of a Proactive Health Care Pathway When Initiating Continuous Subcutaneous Apomorphine Infusion in Patients With Parkinson Disease : Impact on Their Autonomy

Recruiting
N/A
90
Europe
Proactive care pathway
Assistance Publique Hopitaux De Marseille
Parkinson Disease
01/25
07/25
PERSO-PERF, NCT06080399: Personality and Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease

Recruiting
N/A
70
Europe
Continuous subcutaneous apomorphine infusion (CSAI)
University Hospital, Toulouse, ELIVIE France, EVER Pharma France SAS, NHC SAS, France, Orkyn', ETPARK Association, Toulouse, France
Parkinson Disease
04/26
04/26
Lucemyra (lofexidine) / US WorldMeds, Stada
2007-002352-41: Lyhyt ja pitkä buprenorfiini-naloksoni -hoito suonensisäisen buprenorfiiniriippuvuuden vieroitushoidossa. Satunnaistettu kontrolloitu tutkimus

Ongoing
4
120
Europe
Suboxone, BritLofex
Helsingin Diakonissalaitos
Opiaattiriippuvuus, buprenorfiinin suonensisäinen väärinkäyttö
 
 
Bridge, NCT04325659: An Innovative Intervention for OUD Treatment

Recruiting
2/3
75
US
Bridge Device, NSS-2 Bridge Device, Lofexidine, Lucemyra, Placebo, Sham Bridge Device, Sham NSS-2 Bridge Device
Johns Hopkins University, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Opioid-Related Disorders, Opioid Dependence, Opioid Addiction, Opioid Withdrawal
10/25
10/25
PGB-LOF, NCT04218240: Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal

Completed
2
90
US
Pregabalin 200 MG capsules, lyrica, Placebo oral tablet, Lofexidine 0.18Mg Tab, lucemyra
University of Pennsylvania
Opioid Withdrawal
03/23
03/23
NCT03718065: Impact of Lofexidine on Stress, Craving and Opioid Use

Completed
2
112
US
Lofexidine, Lucemyra, Placebo
Medical University of South Carolina, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Opioid-use Disorder, Opiate Dependence
01/24
01/24
NCT06047834: Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids

Active, not recruiting
2
24
US
Standard of Care with Lofexidine, Standard of Care without Lofexidine
USWM, LLC (dba US WorldMeds), National Institute on Drug Abuse (NIDA)
Opioid Withdrawal (Disorder)
05/25
10/26
NCT04360681: Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans

Recruiting
2
120
US
Lofexidine, LFX, Placebo oral tablet, PLB
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, United States Department of Defense, RTI International, Michael E. DeBakey VA Medical Center, USWM, LLC (dba US WorldMeds), Foundation for Advancing Veterans' Health Research
Post Traumatic Stress Disorder, Opioid-use Disorder
12/25
12/25
NCT05027919: Assessing a Clinically-meaningful Opioid Withdrawal Phenotype

Recruiting
2
60
US
Morphine, Naloxone + lofexidine pretreatment, Naloxone + placebo pretreatment, Lofexidine
University of Maryland, Baltimore, National Institute on Drug Abuse (NIDA)
Opioid Withdrawal, Opioid Use Disorder, Opioid Craving
11/25
02/26
UH3, NCT05995535: Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal

Recruiting
2
150
US
LFX/PGB, Lucemyra, lyrica, LFX/PLA-PGB, placebo pregabalin
University of Pennsylvania
Opiate Withdrawal Syndrome, Opioid Use
08/26
08/26
NCT05511909: Evaluating Buspirone to Treat Opioid Withdrawal

Recruiting
2
100
US
Buspirone, Lofexidine, Placebo
Johns Hopkins University
Opioid Use Disorder, Opioid Withdrawal, Opioid Craving, Anxiety
01/27
03/27
NCT05712707: Sublingual Dexmedetomidine for Treating Opioid Withdrawal

Recruiting
1/2
160
US
BXCL501 (180 micrograms), BXCL501 (240 micrograms), Placebo, Lofexidine (Positive Control)
New York State Psychiatric Institute, BioXcel Therapeutics Inc, Yale University, Clinilabs, Inc., National Institute on Drug Abuse (NIDA), CenExel HRI
Opioid Use Disorder, Opioid Withdrawal
06/25
07/25
USWM-LX1-1014, NCT06711640: A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects

Not yet recruiting
1
16
US
LUCEMYRA (lofexidine) tablets
USWM, LLC (dba US WorldMeds), National Institute on Drug Abuse (NIDA)
Opioid Withdrawal (Disorder), Opioid Use Disorder
01/26
02/26
RESTORE, NCT05053503: Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder

Completed
N/A
108
US
Sparrow Ascent Therapy System, Lofexidine, Extended-release injectable naltrexone
Spark Biomedical, Inc., Hazelden Betty Ford Foundation, Gaudenzia, Inc.
Opioid-use Disorder, Opioid Withdrawal
04/25
04/25
Movymia (teriparatide biosimilar) / Stada
ESECTO, NCT05369013: Study and Follow-up of the Clinical Effectiveness and Comparative Safety of Biosimilar Teriparatide in the Management of Postmenopausal or Senile.

Active, not recruiting
N/A
188
Europe
STADA, Spain, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa, Instituto Palacios, Complexo Hospitalario de Ourense, Hospital Universitario Central de Asturias, Hospital Parc Taulí, Sabadell, Hospital Universitario Fundación Jiménez Díaz, Hospital Universitario Infanta Leonor, Hospital Universitario Virgen Macarena, Hospital d´Igualada, Alpha Bioresearch S.L.
Osteoporosis
12/23
04/24
verapamil intralesional / Stada
ACTRN12625000568415: A clinical trial to compare efficacy of intralesional triamcinolone vs intralesional verapamil in patients with keloids/ hypertrophic scars.

Recruiting
4
174
 
Noor ul Huda working as resident in khyber teaching hospital Peshawar.
keloids, hypertrophic scars
 
 
NCT06897969: Comparison of Intralesional Triamcinolone Versus Verapamil for Keloid Treatment

Not yet recruiting
4
60
RoW
Triamcinolone Acetonide 1 ml of 40 mg/mL suspension, Verapamil Injection
Nishtar Medical University
Keloid Scars
09/25
09/25
NCT05855070: Intralesional Hyaluronic Acid and Verapamil Injection in Peyronie's Disease

Not yet recruiting
N/A
42
NA
Intralesional treatment with Hyaluronic acid, Intralesional treatment with Verapamil
Benha University
Peyronie's Disease, Hyaluronic Acid, Verapamil
05/24
05/24
Simlandi (adalimumab-ryvk) / Cipla, Alvotech, Stada, Teva, JAMP Pharma, YAS Holding
2017-003367-35: A Multicenter, Double-blind, Randomized, Parallel-group, Active Control Study to Compare the Efficacy, Safety, and Immunogenicity of AVT02 Versus Humira® in Patients with Moderate-to-Severe Chronic Plaque Psoriasis (ALVOPAD PS)

Not yet recruiting
3
400
Europe
adalimumab, Humira, AVT02, Solution for injection in pre-filled syringe, Humira
Alvotech Swiss AG, Alvotech Swiss AG
Chronic Plaque Psoriasis, Chronic Plaque Psoriasis, Diseases [C] - Immune System Diseases [C20]
 
 
2019-002911-25: Multicenter, Double-blind, Randomized, Parallel-group, Study Evaluating Pharmacokinetic, Efficacy, Safety, and Immunogenicity Between Patients with Moderate to Severe Chronic Plaque Psoriasis Receiving Humira® and Patients Undergoing Repeated Switches Between Humira® and AVT02 Followed by a Safety Extension Phase of AVT02

Not yet recruiting
3
548
Europe
adalimumab, Humira, AVT02, Solution for injection in pre-filled syringe, Humira
Alvotech Swiss AG, Alvotech Swiss AG
Chronic Plaque Psoriasis, Chronic Plaque Psoriasis, Diseases [C] - Immune System Diseases [C20]
 
 
BAT2506 (golimumab biosimilar) / Bio-Thera Solutions, Pharmapark, Stada, Intas, Dr. Reddy’s
2020-002004-39: A study comparing the efficacy and safety of BAT2506 and Simponi® in participants with active psoriatic arthritis Studie porovnávající účinnost a bezpečnost BAT2506 a Simponi® u pacientů s aktivní psoriatickou artritidou

Not yet recruiting
3
700
RoW
BAT2506, proposed golimumab biosimilar, BAT2506, Solution for injection in pre-filled syringe, Simponi®
Bio-Thera Solutions, Ltd., Bio-Thera Solutions, Ltd.
Psoriatic arthritis (PsA), PsA is a chronic, inflammatory form of arthritis associated with psoriasis. The symptoms are oligoarthritis or polyarthritis, pain, swelling, tenderness and rigidity of soft tissues around the joint., Diseases [C] - Immune System Diseases [C20]
 
 
NCT05046431 / 2020-002004-39: Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis

Completed
3
704
RoW
BAT2506, EU Simponi
Bio-Thera Solutions, Bio-Thera Solutions, Ltd.
Psoriatic Arthritis
10/23
10/23
ChiCTR1900022727: A Randomized, Double-blinded, Single-dose, 2-arm Parallel, Comparative Study to Evaluate the Pharmacokinetics and Safety of BAT2506?Injection vs Simponi in Healthy Chinese Male Subjects

Not yet recruiting
1
182
 
BAT2506 injection, 50mg, subcutaneous injection ;Simponi, 50mg, subcutaneous injection
First Hospital of Jilin University; Level of the institution：, self-finance
Psoriatic arthritis/Rheumatoid Arthritis
 
 
NCT05332730: A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi®

Completed
1
375
RoW
BAT2506 injection, Simponi® (EU commercially available product), Simponi® (US commercially available product)
Bio-Thera Solutions, The First Hospital of Jilin University
Psoriatic Arthritis
06/23
07/23
Selarsdi (ustekinumab-aekn) / Alvotech, Fuji Pharma, Cipla, Teva, Stada
2020-004493-22: A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Ustekinumab (AVT04) and Stelara® in Patients With Moderate to Severe Chronic Plaque-type Psoriasis Randomizowane, prowadzone metodą podwójnie ślepej próby, wieloośrodkowe badanie, mające na celu wykazanie równoważnej skuteczności oraz porównanie bezpieczeństwa stosowania i immunogenności biopodobnego ustekinumabu (AVT04) i produktu Stelara® u pacjentów z przewlekłą łuszczycą plackowatą o nasileniu od umiarkowanego do ciężkiego

Not yet recruiting
3
528
Europe
Ustekinumab, Stelara, AVT04, Solution for injection in pre-filled syringe, Stelara
Alvotech Swiss AG, Alvotech Swiss AG
Moderate to Severe Chronic Plaque-type Psoriasis, Moderate to Severe Chronic Plaque-type Psoriasis, Diseases [C] - Immune System Diseases [C20]
 
 
Afiveg (aflibercept low dose biosimilar) / Cipla, Alvotech, Stada, Fuji Pharma, Teva, Polifarma, Advanz Pharma, Servier
ALVOEYE, NCT05155293 / 2021-003651-42: Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea

Completed
3
413
Europe, Japan, RoW
AVT06 (proposed aflibercept biosimilar), Eylea® (Aflibercept)
Alvotech Swiss AG
Neovascular (Wet) AMD
11/23
09/24
ALVOEYE-D, NCT05986786: Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease

Completed
3
35
RoW
Patients will receive 1 IVT injection of AVT06 PFS depending on their chorioretinal vascular disease schedule
Alvotech Swiss AG
Chorioretinal Vascular Disease
04/24
03/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tarpeyo (budesonide) / Calliditas, Stada
NefXtend, NCT06712407: Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

Recruiting
4
60
US
TARPEYO®, delayed-release budesonide capsules
Calliditas Therapeutics AB, Worldwide Clinical Trials
IgA Nephropathy
05/26
11/27
BAIN, NCT07030894: Nefecon and Ambrisentan in IgA Nephropathy

Not yet recruiting
4
129
NA
"Nefecon®","Ambrisentan"
The First Hospital of Jilin University
IgA Nephropathy, Chronic Kidney Disease, Proteinuria
12/26
12/26
Nefigard, NCT03643965 / 2017-004902-16: Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

Completed
3
365
Europe, Canada, US, RoW
Nefecon, Budesonide modified released capsule, Placebo oral capsule, Placebo
Calliditas Therapeutics AB
Primary IgA Nephropathy
07/23
07/23
Nefigard-OLE, NCT04541043 / 2020-003308-14: Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301

Completed
3
119
Europe, Canada, US, RoW
Nefecon 16mg daily
Calliditas Therapeutics AB
Primary IgA Nephropathy
02/24
02/24
NCT05534919: Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301

Completed
3
21
RoW
Nefecon
Everest Medicines (Singapore) Pte. Ltd.
Primary Immunoglobulin a Nephropathy (IgAN)
07/24
07/24
NCT06922305: Relative Bioavailability Study of HR19042 in Healthy Subjects

Completed
1
18
RoW
HR19042 Capsule, Tarpeyo®, Budenofalk®
Jiangsu HengRui Medicine Co., Ltd.
Primary IgA Nephropathy; Autoimmune Hepatitis
01/24
01/24
NCT06589752: Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN

Completed
N/A
200
RoW
TARPEYO 4 MG Delayed Release Oral Capsule, RAS inhibitor
Ruijin Hospital
Primary IgA Nephropathy
09/24
09/24
Apokyn (apomorphine bolus injection) / Stada, Supernus Pharma, Aguettant
2010-019198-14: Icke-motoriska och hälsoekonomiska effekter av intermittent subkutan apomorfinbehandling vid Parkinsons sjukdom

Ongoing
4
30
Europe
Apo-GO Pen, Apo-GO Pen, Apo-GO Pen
Karolinska Universitetssjukhuset Huddinge
Parkinsons sjukdom
 
 
APOMORPHEE, NCT02940912: Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease

Completed
4
45
Europe
Apomorphine, Apokinon, Placebo, Physiologic Serum
Clinique Beau Soleil
Parkinson Disease
01/21
04/21
2010-018650-12: Evaluation du système noradrénergique dans l’altération de la perception douloureuse chez le patient Parkinsonien

Ongoing
3
36
Europe
duloxetine, apomorphine, levodopa, dompéridone, CYMBALTA, APOKINON, MODOPAR, MOTILIUM, CYMBALTA, APOKINON, MODOPAR, MOTILIUM
CHU de Toulouse
maladie de Parkinson
 
 
2016-002454-20: Apomorphine Pump in Early Stage of Parkinson’s Disease Pompe à apomorphine au stade précoce de la maladie de Parkinson

Ongoing
3
192
Europe
APOKINON, Solution for infusion, APOKINON
CHU de Rennes, CHU de Rennes
Parkinson’s disease Maladie de Parkinson, Parkinson’s disease Maladie de Parkinson, Diseases [C] - Nervous System Diseases [C10]
 
 
EARLY-PUMP, NCT02864004: Apomorphine Pump in Early Stage of Parkinson's Disease

Active, not recruiting
3
134
Europe
Apomorphine, Apokinon, Best Medical Treatment
Rennes University Hospital
Parkinson's Disease
12/23
01/25
2004-001929-20: EL TEST DE APOMORFINA COMO MARCADOR BIOLÓGICO DE LAS RECAÍDAS EN PACIENTES DEPENDIENTES DE SUSTANCIAS PSICOTROPAS

Ongoing
2
180
Europe
Ialoprida, APO-go PEN 10 mg/ml solución inyectable, 123I-IBZM, APO-go PEN 10 mg/ml solución inyectable, 123I-IBZM
Servicio de Psiquiatría. Hospital Universitari Vall d’Hebron
Dependencia de alcoholDependencia de cocaínaDependencia de heroína
 
 
APPROVE, NCT06954428: Clinical Trial of Intranasal Delivery of NT-301

Not yet recruiting
1
48
RoW
NT-301 1 mg, NT-301 2 mg, Movapo pen, Placebo 1 mg, Placebo 2 mg, Placebo 3 mg, NT-301 3 mg, NT-301 4 mg, BA NT-301 Nasal spray, Placebo 4 mg
Nano PharmaSolutions Australia
Tolerability of NT-301 Nasal Spray, Pharmacokinetics of NT-301 Nasal Spray, Safety of NT-301 Nasal Spray, Performance of NT-301 Nasal Spray Device
10/25
10/25
Retacrit (epoetin alfa-epbx) / Stada, Norbitec, Pfizer
NCI-2009-01173, NCT00843882: Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Active, not recruiting
3
247
US
Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Epoetin Alfa, EPO, Epoetin alfa-epbx, Epogen, Eprex, Procrit, Retacrit, Laboratory Biomarker Analysis, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid
National Cancer Institute (NCI)
Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome
07/19
10/25
Alymsys (bevacizumab-maly) / Amneal, Pharmaceutical Libbs, Insud Pharma, Nichi-Iko, Stada
NCT04408989: A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and US Licensed-Avastin®.

Completed
1
114
RoW
MB02-SP, MB02-SP (Bevacizumab Biosimilar), MB02-DM, MB02-DM (Bevacizumab Biosimilar), US licenced Avastin®, Bevacizumab (US sourced)
mAbxience Research S.L.
Healthy Volunteers
08/21
09/21
NCT06313268: Safety of Effivia®, a Bevacizumab Biosimilar

Completed
N/A
83
RoW
Bevacizumab Biosimilar MB02, Effivia®
Laboratorios Liomont, Servicios Especializados en Ensayos Clínicos, S.C.
Metastatic Colorectal Cancer, Metastatic Cervical Cancer, Non Squamous Non Small Cell Lung Cancer
04/24
09/24
APO-go (apomorphine continuous subcutaneous infusion) / Stada, Kyowa Kirin, Endo, Supernus Pharma
INFUS-ON, NCT02339064: Infusion of Apomorphine: Long-term Safety Study

Active, not recruiting
3
99
US
apomorphine infusion
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Idiopathic Parkinson's Disease
12/18
12/25
APODoC, NCT05213169: Apomorphine in Severe Brain-injured Patients

Recruiting
2/3
48
Europe
Apomorphine Hydrochloride 5mg/ml, Sodium chloride 9mg/ml
University of Liege, Centre Hospitalier Neurologique William Lennox (Belgium), Hôpital Valdor - ISoSL (Belgium), VITHAS hospitales (Spain)
Disorder of Consciousness
12/26
12/26
2018-003144-23: Treating severe brain-injured patients with apomorphine Traitement des patients cérébro-lésés avec l'apomorphine

Not yet recruiting
2
54
Europe
Solution for infusion in pre-filled syringe, APO-go® PFS 5 mg/ml Solution for Infusion in Pre-filled Syringe
University of Liège, NeuroHealing Pharmaceuticals Inc., Britannia Pharmaceuticals Limited
Disorders of consciousness Troubles de l'état de conscience, Disorders of consciousness Troubles de la conscience, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT03623828: Treating Severe Brain-injured Patients With Apomorphine

Active, not recruiting
2
8
Europe
Apomorphine Hydrochloride 50Mg/10mL Prefilled Syringe, APO-go PFS 5mg/ml
University of Liege, Université Catholique de Louvain
Disorder of Consciousness
04/21
11/22
2019-003315-60: A study investigating the effect and safety of a new potential drug for Parkinson's disease patients.

Ongoing
1/2
46
Europe
APO-go®, APORON, Solution for injection/infusion, Suspension and solution for spray, Apo-go
Criceto IKM B.V., Criceto
Parkinson's Disease, Parkinson, Diseases [C] - Nervous System Diseases [C10]
 
 
AUTAP, NCT05405998: Development of a Proactive Health Care Pathway When Initiating Continuous Subcutaneous Apomorphine Infusion in Patients With Parkinson Disease : Impact on Their Autonomy

Recruiting
N/A
90
Europe
Proactive care pathway
Assistance Publique Hopitaux De Marseille
Parkinson Disease
01/25
07/25
PERSO-PERF, NCT06080399: Personality and Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease

Recruiting
N/A
70
Europe
Continuous subcutaneous apomorphine infusion (CSAI)
University Hospital, Toulouse, ELIVIE France, EVER Pharma France SAS, NHC SAS, France, Orkyn', ETPARK Association, Toulouse, France
Parkinson Disease
04/26
04/26
Lucemyra (lofexidine) / US WorldMeds, Stada
2007-002352-41: Lyhyt ja pitkä buprenorfiini-naloksoni -hoito suonensisäisen buprenorfiiniriippuvuuden vieroitushoidossa. Satunnaistettu kontrolloitu tutkimus

Ongoing
4
120
Europe
Suboxone, BritLofex
Helsingin Diakonissalaitos
Opiaattiriippuvuus, buprenorfiinin suonensisäinen väärinkäyttö
 
 
Bridge, NCT04325659: An Innovative Intervention for OUD Treatment

Recruiting
2/3
75
US
Bridge Device, NSS-2 Bridge Device, Lofexidine, Lucemyra, Placebo, Sham Bridge Device, Sham NSS-2 Bridge Device
Johns Hopkins University, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Opioid-Related Disorders, Opioid Dependence, Opioid Addiction, Opioid Withdrawal
10/25
10/25
PGB-LOF, NCT04218240: Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal

Completed
2
90
US
Pregabalin 200 MG capsules, lyrica, Placebo oral tablet, Lofexidine 0.18Mg Tab, lucemyra
University of Pennsylvania
Opioid Withdrawal
03/23
03/23
NCT03718065: Impact of Lofexidine on Stress, Craving and Opioid Use

Completed
2
112
US
Lofexidine, Lucemyra, Placebo
Medical University of South Carolina, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Opioid-use Disorder, Opiate Dependence
01/24
01/24
NCT06047834: Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids

Active, not recruiting
2
24
US
Standard of Care with Lofexidine, Standard of Care without Lofexidine
USWM, LLC (dba US WorldMeds), National Institute on Drug Abuse (NIDA)
Opioid Withdrawal (Disorder)
05/25
10/26
NCT04360681: Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans

Recruiting
2
120
US
Lofexidine, LFX, Placebo oral tablet, PLB
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, United States Department of Defense, RTI International, Michael E. DeBakey VA Medical Center, USWM, LLC (dba US WorldMeds), Foundation for Advancing Veterans' Health Research
Post Traumatic Stress Disorder, Opioid-use Disorder
12/25
12/25
NCT05027919: Assessing a Clinically-meaningful Opioid Withdrawal Phenotype

Recruiting
2
60
US
Morphine, Naloxone + lofexidine pretreatment, Naloxone + placebo pretreatment, Lofexidine
University of Maryland, Baltimore, National Institute on Drug Abuse (NIDA)
Opioid Withdrawal, Opioid Use Disorder, Opioid Craving
11/25
02/26
UH3, NCT05995535: Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal

Recruiting
2
150
US
LFX/PGB, Lucemyra, lyrica, LFX/PLA-PGB, placebo pregabalin
University of Pennsylvania
Opiate Withdrawal Syndrome, Opioid Use
08/26
08/26
NCT05511909: Evaluating Buspirone to Treat Opioid Withdrawal

Recruiting
2
100
US
Buspirone, Lofexidine, Placebo
Johns Hopkins University
Opioid Use Disorder, Opioid Withdrawal, Opioid Craving, Anxiety
01/27
03/27
NCT05712707: Sublingual Dexmedetomidine for Treating Opioid Withdrawal

Recruiting
1/2
160
US
BXCL501 (180 micrograms), BXCL501 (240 micrograms), Placebo, Lofexidine (Positive Control)
New York State Psychiatric Institute, BioXcel Therapeutics Inc, Yale University, Clinilabs, Inc., National Institute on Drug Abuse (NIDA), CenExel HRI
Opioid Use Disorder, Opioid Withdrawal
06/25
07/25
USWM-LX1-1014, NCT06711640: A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects

Not yet recruiting
1
16
US
LUCEMYRA (lofexidine) tablets
USWM, LLC (dba US WorldMeds), National Institute on Drug Abuse (NIDA)
Opioid Withdrawal (Disorder), Opioid Use Disorder
01/26
02/26
RESTORE, NCT05053503: Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder

Completed
N/A
108
US
Sparrow Ascent Therapy System, Lofexidine, Extended-release injectable naltrexone
Spark Biomedical, Inc., Hazelden Betty Ford Foundation, Gaudenzia, Inc.
Opioid-use Disorder, Opioid Withdrawal
04/25
04/25
Movymia (teriparatide biosimilar) / Stada
ESECTO, NCT05369013: Study and Follow-up of the Clinical Effectiveness and Comparative Safety of Biosimilar Teriparatide in the Management of Postmenopausal or Senile.

Active, not recruiting
N/A
188
Europe
STADA, Spain, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa, Instituto Palacios, Complexo Hospitalario de Ourense, Hospital Universitario Central de Asturias, Hospital Parc Taulí, Sabadell, Hospital Universitario Fundación Jiménez Díaz, Hospital Universitario Infanta Leonor, Hospital Universitario Virgen Macarena, Hospital d´Igualada, Alpha Bioresearch S.L.
Osteoporosis
12/23
04/24
verapamil intralesional / Stada
ACTRN12625000568415: A clinical trial to compare efficacy of intralesional triamcinolone vs intralesional verapamil in patients with keloids/ hypertrophic scars.

Recruiting
4
174
 
Noor ul Huda working as resident in khyber teaching hospital Peshawar.
keloids, hypertrophic scars
 
 
NCT06897969: Comparison of Intralesional Triamcinolone Versus Verapamil for Keloid Treatment

Not yet recruiting
4
60
RoW
Triamcinolone Acetonide 1 ml of 40 mg/mL suspension, Verapamil Injection
Nishtar Medical University
Keloid Scars
09/25
09/25
NCT05855070: Intralesional Hyaluronic Acid and Verapamil Injection in Peyronie's Disease

Not yet recruiting
N/A
42
NA
Intralesional treatment with Hyaluronic acid, Intralesional treatment with Verapamil
Benha University
Peyronie's Disease, Hyaluronic Acid, Verapamil
05/24
05/24
Simlandi (adalimumab-ryvk) / Cipla, Alvotech, Stada, Teva, JAMP Pharma, YAS Holding
2017-003367-35: A Multicenter, Double-blind, Randomized, Parallel-group, Active Control Study to Compare the Efficacy, Safety, and Immunogenicity of AVT02 Versus Humira® in Patients with Moderate-to-Severe Chronic Plaque Psoriasis (ALVOPAD PS)

Not yet recruiting
3
400
Europe
adalimumab, Humira, AVT02, Solution for injection in pre-filled syringe, Humira
Alvotech Swiss AG, Alvotech Swiss AG
Chronic Plaque Psoriasis, Chronic Plaque Psoriasis, Diseases [C] - Immune System Diseases [C20]
 
 
2019-002911-25: Multicenter, Double-blind, Randomized, Parallel-group, Study Evaluating Pharmacokinetic, Efficacy, Safety, and Immunogenicity Between Patients with Moderate to Severe Chronic Plaque Psoriasis Receiving Humira® and Patients Undergoing Repeated Switches Between Humira® and AVT02 Followed by a Safety Extension Phase of AVT02

Not yet recruiting
3
548
Europe
adalimumab, Humira, AVT02, Solution for injection in pre-filled syringe, Humira
Alvotech Swiss AG, Alvotech Swiss AG
Chronic Plaque Psoriasis, Chronic Plaque Psoriasis, Diseases [C] - Immune System Diseases [C20]
 
 
BAT2506 (golimumab biosimilar) / Bio-Thera Solutions, Pharmapark, Stada, Intas, Dr. Reddy’s
2020-002004-39: A study comparing the efficacy and safety of BAT2506 and Simponi® in participants with active psoriatic arthritis Studie porovnávající účinnost a bezpečnost BAT2506 a Simponi® u pacientů s aktivní psoriatickou artritidou

Not yet recruiting
3
700
RoW
BAT2506, proposed golimumab biosimilar, BAT2506, Solution for injection in pre-filled syringe, Simponi®
Bio-Thera Solutions, Ltd., Bio-Thera Solutions, Ltd.
Psoriatic arthritis (PsA), PsA is a chronic, inflammatory form of arthritis associated with psoriasis. The symptoms are oligoarthritis or polyarthritis, pain, swelling, tenderness and rigidity of soft tissues around the joint., Diseases [C] - Immune System Diseases [C20]
 
 
NCT05046431 / 2020-002004-39: Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis

Completed
3
704
RoW
BAT2506, EU Simponi
Bio-Thera Solutions, Bio-Thera Solutions, Ltd.
Psoriatic Arthritis
10/23
10/23
ChiCTR1900022727: A Randomized, Double-blinded, Single-dose, 2-arm Parallel, Comparative Study to Evaluate the Pharmacokinetics and Safety of BAT2506?Injection vs Simponi in Healthy Chinese Male Subjects

Not yet recruiting
1
182
 
BAT2506 injection, 50mg, subcutaneous injection ;Simponi, 50mg, subcutaneous injection
First Hospital of Jilin University; Level of the institution：, self-finance
Psoriatic arthritis/Rheumatoid Arthritis
 
 
NCT05332730: A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi®

Completed
1
375
RoW
BAT2506 injection, Simponi® (EU commercially available product), Simponi® (US commercially available product)
Bio-Thera Solutions, The First Hospital of Jilin University
Psoriatic Arthritis
06/23
07/23
Selarsdi (ustekinumab-aekn) / Alvotech, Fuji Pharma, Cipla, Teva, Stada
2020-004493-22: A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Ustekinumab (AVT04) and Stelara® in Patients With Moderate to Severe Chronic Plaque-type Psoriasis Randomizowane, prowadzone metodą podwójnie ślepej próby, wieloośrodkowe badanie, mające na celu wykazanie równoważnej skuteczności oraz porównanie bezpieczeństwa stosowania i immunogenności biopodobnego ustekinumabu (AVT04) i produktu Stelara® u pacjentów z przewlekłą łuszczycą plackowatą o nasileniu od umiarkowanego do ciężkiego

Not yet recruiting
3
528
Europe
Ustekinumab, Stelara, AVT04, Solution for injection in pre-filled syringe, Stelara
Alvotech Swiss AG, Alvotech Swiss AG
Moderate to Severe Chronic Plaque-type Psoriasis, Moderate to Severe Chronic Plaque-type Psoriasis, Diseases [C] - Immune System Diseases [C20]
 
 
Afiveg (aflibercept low dose biosimilar) / Cipla, Alvotech, Stada, Fuji Pharma, Teva, Polifarma, Advanz Pharma, Servier
ALVOEYE, NCT05155293 / 2021-003651-42: Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea

Completed
3
413
Europe, Japan, RoW
AVT06 (proposed aflibercept biosimilar), Eylea® (Aflibercept)
Alvotech Swiss AG
Neovascular (Wet) AMD
11/23
09/24
ALVOEYE-D, NCT05986786: Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease

Completed
3
35
RoW
Patients will receive 1 IVT injection of AVT06 PFS depending on their chorioretinal vascular disease schedule
Alvotech Swiss AG
Chorioretinal Vascular Disease
04/24
03/25

Download Options